Kathy Miller

  • 14762 Citations
  • 52 h-Index
1976 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Publications

Filter
Review article
2018

E2112: Randomized phase III trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer

Yeruva, S. L. H., Zhao, F., Miller, K. D., Tevaarwerk, A. J., Wagner, L. I., Gray, R. J., Sparano, J. A. & Connolly, R. M., Dec 1 2018, In : npj Breast Cancer. 4, 1, 4.

Research output: Contribution to journalReview article

18 Scopus citations
2012

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

Schneider, B. P., Shen, F. & Miller, K. D., Oct 1 2012, In : The lancet oncology. 13, 10, p. e427-e436

Research output: Contribution to journalReview article

30 Scopus citations
2009

Independent review of E2100: A phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

Gray, R., Bhattacharya, S., Bowden, C., Miller, K. & Comis, R. L., Oct 20 2009, In : Journal of Clinical Oncology. 27, 30, p. 4966-4972 7 p.

Research output: Contribution to journalReview article

233 Scopus citations

The role of vascular endothelial growth factor genetic variability in cancer

Schneider, B. P., Radovich, M. & Miller, K. D., Sep 1 2009, In : Clinical Cancer Research. 15, 17, p. 5297-5302 6 p.

Research output: Contribution to journalReview article

65 Scopus citations
2008

Clinical-translational approaches to the Nm23-H1 metastasis Suppressor

Steeg, P. S., Horak, C. E. & Miller, K. D., Aug 15 2008, In : Clinical Cancer Research. 14, 16, p. 5006-5012 7 p.

Research output: Contribution to journalReview article

70 Scopus citations

Development of new targeted therapies for breast cancer.

Doyle, D. M. & Miller, K. D., 2008, In : Cancer treatment and research. 141, p. 119-134 16 p.

Research output: Contribution to journalReview article

6 Scopus citations

Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling.

Mamounas, E., Budd, G. T. & Miller, K., Feb 2008, In : Clinical advances in hematology & oncology : H&O. 6, 2, p. s1-s8

Research output: Contribution to journalReview article

1 Scopus citations
2007

Antiangiogenic agents in breast cancer

Salter, J. T. & Miller, K. D., Oct 1 2007, In : Cancer Investigation. 25, 7, p. 518-526 9 p.

Research output: Contribution to journalReview article

14 Scopus citations
2005

Angiogenesis of breast cancer

Schneider, B. P. & Miller, K. D., Dec 1 2005, In : Journal of Clinical Oncology. 23, 8, p. 1782-1790 9 p.

Research output: Contribution to journalReview article

235 Scopus citations

Can tumor angiogenesis be inhibited without resistance?

Miller, K. D., Sweeney, C. J. & Sledge, G. W., 2005, In : EXS. 94, p. 95-112 18 p.

Research output: Contribution to journalReview article

54 Scopus citations
2004

Breast cancer: The role of angiogenesis and antiangiogenic therapy

Miller, K. D. & Dul, C. L., Oct 1 2004, In : Hematology/Oncology Clinics of North America. 18, 5, p. 1071-1086 16 p.

Research output: Contribution to journalReview article

14 Scopus citations

The role of ErbB inhibitors in trastuzumab resistance

Miller, K. D., Jun 22 2004, In : Oncologist. 9, SUPPL. 3, p. 16-19 4 p.

Research output: Contribution to journalReview article

31 Scopus citations
2003

Resistance in the anti-angiogenic era: Nay-saying or a word of caution?

Sweeney, C. J., Miller, K. D. & Sledge, G. W., Jan 1 2003, In : Trends in Molecular Medicine. 9, 1, p. 24-29 6 p.

Research output: Contribution to journalReview article

42 Scopus citations

The Snark is a Boojum: The continuing problem of drug resistance in the antiangiogenic era

Miller, K. D., Sweeney, C. J. & Sledge, G. W., Jan 1 2003, In : Annals of Oncology. 14, 1, p. 20-28 9 p.

Research output: Contribution to journalReview article

41 Scopus citations
2002

Angiogenesis and antiangiogenic therapy

Sledge, G. W. & Miller, K. D., May 13 2002, In : Current problems in cancer. 26, 1, p. 1-60 60 p.

Research output: Contribution to journalReview article

27 Scopus citations

Diätetische prävention des mamma- und prostatakarzinoms: Grundlagen und praxis des Nutritional Cancer Prevention (NCP)-programms

Translated title of the contribution: Dietary prevention of carcinornas of the breast and prostate: Fundamental and practical aspects of the Nutritional Cancer Prevention (NCP) programEbert, T., Kleine-Gunk, B., Altwein, J. E., Miller, K. & Mallmann, P., Jun 21 2002, In : Deutsche Medizinische Wochenschrift. 127, 25-26, p. 1392-1396 5 p.

Research output: Contribution to journalReview article

3 Scopus citations
2001

Adjuvant chemotherapy for tumors of one centimeter or less: the law of diminishing returns.

Soule, S. E. & Miller, K. D., Nov 2001, In : Current oncology reports. 3, 6, p. 529-535 7 p.

Research output: Contribution to journalReview article

Redefining the target: Chemotherapeutics as antiangiogenics

Miller, K. D., Sweeney, C. J. & Sledge, J., Feb 15 2001, In : Journal of Clinical Oncology. 19, 4, p. 1195-1206 12 p.

Research output: Contribution to journalReview article

371 Scopus citations
2000

High-dose chemotherapy in breast cancer -- the perils of history uncontrolled.

Miller, K. D. & Sledge, G. W., Jan 1 2000, In : Medscape women's health. 5, 3, p. E1

Research output: Contribution to journalReview article

1 Scopus citations
1999

Taxanes in the treatment of breast cancer: A prodigy comes of age

Miller, K. D. & Sledge, G. W., Mar 16 1999, In : Cancer Investigation. 17, 2, p. 121-136 16 p.

Research output: Contribution to journalReview article

45 Scopus citations

Toward checkmate: Biology and breast cancer therapy for the new millennium

Miller, K. D. & Sledge, G. W., Dec 1 1999, In : Investigational New Drugs. 17, 4, p. 417-427 11 p.

Research output: Contribution to journalReview article

7 Scopus citations